PDL BioPharma, Inc. has received $0.13 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $0.1 while the top line estimate is $0.16 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -78.69%.
PDL BioPharma, Inc. results fell short with a surprise EPS of -21.43% or $-0.03. The Actual EPS was $0.11 compared to the Estimated EPS of $0.14 during its most recent quarterly earnings. Incline Village based PDL BioPharma, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 27, 2017.
PDL BioPharma, Inc. has a Price to Earnings ratio of 1.65 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 0.48. For the Most Recent Fiscal Year, PDL BioPharma, Inc. has a price to cash ratio of 1.04. For the Trailing twelve month period, company showed a Net Profit Margin of 49.04% and Return on Equity of the stock is 29.87%.
In the last quarter, PDL BioPharma, Inc. reported Annual Earnings of $0.11. Based on the filings, last years Annual Earnings was, $2.03. In the last Quarter, PDLI reported a surprise Earnings per Share of -21.43% . The consensus estimate for current quarter is $0.13 and for the current fiscal year, the estimate is $0.58. For the Next fiscal year, the estimate is $0.2 based on the consensus.
PDL BioPharma, Inc. (NASDAQ:PDLI) witnessed a volatile trading activity on Tuesday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $2.18 and reached the intraday high at $2.24. The bulls started the profit booking and pushed the shares to intraday low of $2.14. The trading session was marked by a volume range of 2,143,114 shares exchanging hands. The 52-week high of the shares is $3.84 and the 52-week low is $1.93. The market cap of the company stands at $364 million and there are 165,540,750 shares in public circulation.
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.